Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Nipocalimab in Adult Participants with Active Lupus Nephritis
2020-005568-79Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Complete renal response (CRR). Started Jul 2021; status: completed.
02
Drugs
nipocalimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2020-005568-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005568-79.